Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China
查看参考文献17篇
|
文摘
|
Background: Elderly multiple myeloma (MM) patients often tend to suffer a variety of diseases, so the treatment of choice is very difficult for the elderly myeloma patients. The overall survival (OS) time and side effects with elderly patients are unclear in China. The study tried to find out the role of geriatric assessment in the Chinese elderly MM. Methods: We retrospectively analyzed the data of628 newly diagnosed patients from six hospitals from June 2011 to June 2013. A geriatric assessment: had been performed to assess comorbidities, cognitive, and physical status for these patients. The primary endpoint was to evaluate different physical states of elderly patients with OS time and treatment-related side effects. Results: An additive scoring system (range: 0-5), based on age, Katz's Activity of Daily Living (ADL) and Lawton's Instrumental Activity of Daily Living (IADL) ≤5 and Charlson Comorbidity Index (CCI) was developed to identify three groups: fit (score = 0); intermediate-fitness (score =1); and frail (score ≥2). The 3-year OS was 63% in fit patients, 63% in intermediate-fitness patients, and 49% in frail patients ≥3 hematologic adverse events (AEs) were documented in 45 (35.4%) fit, 34 (34%) intermediate-fitness, and 121 (30.2%) frail patients. The risk of a grade ≥3 hematologic AEs was not significantly increase in intermediate-fitness (hazard ratios [HR]: 0.99,95% confidence interval [CI]: 0.54-1.47, P= 1.000) and in frail patients (HR: 1.16, 95% CI: 0.70-1.93, P = 0.558) compared with fit ones. Conclusions: MM occurs earlier in life and being advanced when the diagnosis is made in the mainland of China. The overall survival in frailty with International Staging System (ISS) II/III was the worst in all patients. |
|
来源
|
Chinese Medical Journal
,2017,130(2):130-134 【核心库】
|
|
DOI
|
10.4103/0366-6999.197977
|
|
关键词
|
Geriatric Assessment
;
Multicenter Study
;
Multiple Myeloma
|
|
地址
|
1.
Department of Hematology, Beijing Chaoyang Hospital (West), Capital Medical University, Beijing University Clinical Research Institute, Beijing, 100043
2.
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Cancer Hospital, Tianjin, 300000
3.
Department of Hematology, Shengjing Hospital of China Medical University, Liaoning, Shenyang, 110004
4.
Department of Hematology, The People's Liberation Army 301 Hospital, Beijing, 100853
5.
Department of Hematology, The People's Liberation Army 304 Hospital, Beijing, 100048
6.
Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing, 100044
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
0366-6999 |
|
学科
|
医药、卫生 |
|
基金
|
supported by a grant from the National Natural Science Foundation of China
|
|
文献收藏号
|
CSCD:5900084
|
参考文献 共
17
共1页
|
|
1.
Palumbo A. Multiple myeloma.
N Engl J Med,2011,364:1046-1060
|
CSCD被引
66
次
|
|
|
|
|
2.
San Miguel J F. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med,2008,359:906-917
|
CSCD被引
34
次
|
|
|
|
|
3.
Fayers P M. Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Blood,2011,118:1239-1247
|
CSCD被引
9
次
|
|
|
|
|
4.
Palumbo A. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
N Engl J Med,2012,366:1759-1769
|
CSCD被引
12
次
|
|
|
|
|
5.
San Miguel J F. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Haematologica,2015,100:1334-1339
|
CSCD被引
1
次
|
|
|
|
|
6.
Mols F. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry.
Eur J Haematol,2012,89:311-319
|
CSCD被引
1
次
|
|
|
|
|
7.
Chng W J. IMWG consensus on risk stratification in multiple myeloma.
Leukemia,2014,28:269-277
|
CSCD被引
35
次
|
|
|
|
|
8.
Kumar S K. Continued improvement in survival in multiple myeloma and the impact of novel agents.
Blood,2012,120:3972
|
CSCD被引
1
次
|
|
|
|
|
9.
Siegel D S. Age is not a prognostic variable with autotransplants for multiple myeloma.
Blood,1999,93:51-54
|
CSCD被引
4
次
|
|
|
|
|
10.
Palumbo A. Safety of thalidomide in newly diagnosed elderly myeloma patients: A meta-analysis of data from individual patients in six randomized trials.
Haematologica,2013,98:87-94
|
CSCD被引
2
次
|
|
|
|
|
11.
Hamaker M E. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: A systematic review.
Lancet Oncol,2012,13:e437-e444
|
CSCD被引
7
次
|
|
|
|
|
12.
Larocca A. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Leukemia,2016,30:1320-1326
|
CSCD被引
1
次
|
|
|
|
|
13.
Lu J. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: Results of a multicenter analysis.
Blood Cancer J,2014,4:e239
|
CSCD被引
36
次
|
|
|
|
|
14.
Palumbo A. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report.
Blood,2015,125:2068-2074
|
CSCD被引
21
次
|
|
|
|
|
15.
Larocca A. How I treat fragile myeloma patients.
Blood,2015,126:2179-2185
|
CSCD被引
2
次
|
|
|
|
|
16.
Maes H. Optimizing quality of life in multiple myeloma patients: Current options, challenges and recommendations.
Expert Rev Hematol,2015,8:355-366
|
CSCD被引
2
次
|
|
|
|
|
17.
Lyu W W. Thalidomide-based regimens for elderly and/or transplant ineligible patients with multiple myeloma: A meta-analysis.
Chin Med J,2016,129:320-325
|
CSCD被引
1
次
|
|
|
|
|
了解气象卫星更多信息，请访问